RESEARCH PAPER
FGFR2 gene expression analysis in colon cancer patients treated with first‑line chemotherapy based on fluoropyrimidine
More details
Hide details
1
Zakład Patomorfologii CSK MON WIM w Warszawie; kierownik: cz.p.o.ppłk. dr n. med. Szczepan Cierniak
2
Celon Pharma S.A., Dział Badań Przedklinicznych; kierownik działu: dr n. med. Jerzy Pieczykolan
3
Zakład Patologii COI w Warszawie; kierownik: prof. dr hab. n. med. Monika Prochorec‑Sobieszek
4
Klinika Onkologii CSK MON WIM; kierownik: prof. dr hab. n. med. Cezary Szczylik
Submission date: 2017-08-28
Publication date: 2018-04-09
LW 2018;96(2):112-119
KEYWORDS
ABSTRACT
Background. The aim of the study was an assessment of frequency and significance of FGFR2 receptor
expression and its gene amplification as a potential prognostic and predictor factor. Methods. The presence of FGFR2
gene amplification and expression FGFR2 receptor was assessed in formalin‑fixed, paraffin‑embedded tissues using,
respectively, a FISH assay and an IHC in an advanced gastric cancer cohort. In this pilot study, clinical data of 36 patients
treated with first‑line chemotherapy based on fluoropyrimidine derivatives was analyzed. Results. One of 36 patients
(3%) exhibited FGFR2 amplification. FGFR2 receptor expression was observed in 11% (4/36) patients, and overexpression
of this receptor was observed in 6% (2/36) of them. In univariate analysis, PFS and OS did not differ between expressed
FGFR2 and no expression groups. Multivariate analysis indicated that FGFR2 expression was not an independent predictor
and prognostic factor for PFS and OS, respectively. Conclusion. FGFR 2 expression does not appear to be an independent
prognostic and predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine chemotherapy.
CONFLICT OF INTEREST
No conflicts of interest were declared.